Unknown

Dataset Information

0

Differential efficacy of three cycles of CMF followed by tamoxifen in patients with ER-positive and ER-negative tumors: long-term follow up on IBCSG Trial IX.


ABSTRACT:

Background

The benefit of adjuvant chemotherapy in postmenopausal patients with estrogen receptor (ER)-positive lymph node-negative breast cancer is being reassessed.

Patients and methods

After stratification by ER status, 1669 postmenopausal patients with operable lymph node-negative breast cancer were randomly assigned to three 28-day courses of 'classical' CMF (cyclophosphamide, methotrexate, 5-fluorouracil) chemotherapy followed by tamoxifen for 57 months (CMF?tamoxifen) or to tamoxifen alone for 5 years.

Results

ERs were positive in 81% of tumors. At a median follow-up of 13.1 years, patients with ER-positive breast cancers did not benefit from CMF [13-year disease-free survival (DFS) 64% CMF?tamoxifen, 66% tamoxifen; P = 0.99], whereas CMF substantially improved the prognosis of patients with ER-negative breast cancer (13-year DFS 73% versus 57%, P = 0.001). Similarly, breast cancer-free interval (BCFI) was identical in the ER-positive cohort but significantly improved by chemotherapy in the ER-negative cohort (13-year BCFI 80% versus 63%, P = 0.001). CMF had no influence on second nonbreast malignancies or deaths from other causes.

Conclusion

CMF is not beneficial in postmenopausal patients with node-negative ER-positive breast cancer but is highly effective within the ER-negative cohort. In the future, other markers of chemotherapy response may define a subset of patients with ER-positive tumors who may benefit from adjuvant chemotherapy.

SUBMITTER: Aebi S 

PROVIDER: S-EPMC3202167 | BioStudies | 2011-01-01

REPOSITORIES: biostudies

Similar Datasets

2016-01-01 | S-EPMC4962708 | BioStudies
2004-01-01 | S-EPMC2409769 | BioStudies
2019-01-01 | S-EPMC6387478 | BioStudies
1000-01-01 | S-EPMC4749471 | BioStudies
2017-01-01 | S-EPMC5597253 | BioStudies
2006-01-01 | S-EPMC1557737 | BioStudies
2015-01-01 | S-EPMC4763278 | BioStudies
2020-01-01 | S-EPMC6990911 | BioStudies
2014-01-01 | S-EPMC4232733 | BioStudies
2015-01-01 | S-EPMC4658543 | BioStudies